Journal
BEHAVIOURAL BRAIN RESEARCH
Volume 225, Issue 1, Pages 328-333Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.bbr.2011.07.024
Keywords
Depression; Ascorbic acid; NMDA; L-arginine; Nitric oxide; Tail suspension test
Categories
Funding
- FINEP [01.06.0842-00]
- CNPq
- CAPES
Ask authors/readers for more resources
Clinical and preclinical data reported that ascorbic acid has antidepressant properties. The present study was designed to investigate the participation of L-arginine-NO-cGMP pathway in the antidepressant-like effect of ascorbic acid in the tail suspension test (TST) in mice. The antidepressant-like effect of ascorbic acid (1 mg/kg, p.o.) in the TST was prevented by the pre-treatment of mice with NMDA (0.1 pmol/site, icy.), L-arginine (750 mg/kg, i.p., a substrate for nitric oxide synthase) or sildenafil (5 mg/kg, i.p., a phosphodiesterase 5 inhibitor). The administration of MK-801 (0.001 mg/kg, i.p), 7-nitroindazole (25 mg/kg, i.p., a neuronal nitric oxide synthase inhibitor) or ODQ (30 pmol/site i.c.v., a soluble guanylate cyclase inhibitor) in combination with a sub-effective dose of ascorbic acid (0.1 mg/kg, p.o.) reduced the immobility time in the TST test when compared with either drug alone. None of the results in the TST appears to be due to a nonspecific locomotor effect. Our findings provide evidence that the effect of ascorbic acid in the TST involve an interaction with NMDA receptors and L-arginine-NO-cGMP pathway, contributing to the understanding of the mechanisms underlying the antidepressant-like effect of this vitamin. (C) 2011 Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available